| Literature DB >> 27197048 |
Andrew D Wiese, Carlos G Grijalva, Yuwei Zhu, Edward F Mitchel, Marie R Griffin.
Abstract
Introduction of pneumococcal conjugate vaccines in the childhood immunization schedule was associated with decreases in all-cause pneumonia hospitalizations among black and white children in Tennessee, USA. Although racial disparities that existed before introduction of these vaccines have been substantially reduced, rates remain higher in boys than in girls among young children.Entities:
Keywords: 13-valent pneumococcal conjugate vaccine; 7-valent pneumococcal conjugate vaccine; PCV13; PCV7; Tennessee; United States; bacteria; children; health status disparities; hospitalization; invasive pneumococcal disease; pneumococcal conjugate vaccine; pneumococci; pneumonia; race; sex; vaccines
Year: 2016 PMID: 27197048 PMCID: PMC4880071 DOI: 10.3201/eid2206.152023
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Pre-PCV7 and post-PCV13 annualized pneumonia rates, by age, sex, and race, and hospitalizations per 1,000 children, Tennessee, USA, 1998–2013*
| Patient age, y, and race | Patient sex | Hospitalizations/1,000 children | Post-PCV13 vs. pre-PCV7 | |||
|---|---|---|---|---|---|---|
| Pre-PCV7, 1998–1999, 11,059 hospitalizations | Post-PCV13, 2011–2013, 9,171 hospitalizations | Rate ratio (95% CI) | Rate difference (95% CI)† | |||
| All‡ |
| 4.0 | 2.0 |
| 0.51 (0.50–0.52) | −2.0 (−2.1 to −1.9) |
| <2‡ | 18.4 | 7.3 | 0.40 (0.38–0.41) | −11.1 (−11.6 to −10.6) | ||
| Black | M | 27.1 | 8.5 | 0.31 (0.28–0.35) | −18.6 (−20.5 to −16.6) | |
| Black | F | 20.0 | 6.4 | 0.32 (0.28–0.37) | −13.6 (−15.3 to −11.9) | |
| White | M | 18.0 | 7.8 | 0.43 (0.40–0.46) | −10.2 (−11.1 to −9.3) | |
| White | F | 14.5 | 6.2 |
| 0.43 (0.40–0.47) | −8.2 (−9.0 to −7.4) |
| 2–4‡ | 5.4 | 3.0 | 0.56 (0.52–0.59) | −2.4 (−2.6 to −2.1) | ||
| Black | M | 6.6 | 3.4 | 0.50 (0.43–0.59) | −3.3 (−4.1 to −2.5) | |
| Black | F | 5.3 | 3.1 | 0.58 (0.49–0.70) | −2.2 (−3.0 to −1.5) | |
| White | M | 5.3 | 3.0 | 0.56 (0.51–0.62) | −2.3 (−2.7 to −1.9) | |
| White | F | 5.0 | 2.9 |
| 0.59 (0.53–0.65) | −2.0 (−2.4 to −1.6) |
| 5–17‡ | 1.6 | 1.1 | 0.67 (0.63–0.70) | −0.5 (−0.6 to −0.5) | ||
| Black | M | 2.0 | 1.1 | 0.57 (0.49–0.65) | −0.8 (−1.1 to −0.6) | |
| Black | F | 1.6 | 1.0 | 0.61 (0.53–0.71) | −0.6 (−0.8 to −0.4) | |
| White | M | 1.6 | 1.1 | 0.70 (0.65–0.75) | −0.5 (−0.6 to −0.4) | |
| White | F | 1.6 | 1.2 | 0.74 (0.68–0.80) | −0.4 (−0.5 to −0.3) | |
*PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine. †For hospitalizations per 1,000 children. ‡Includes all race/ethnicity categories (black, white, Hispanic, other). These estimates were not different from estimates including only black and white children.
FigureAnnualized all-cause pneumonia hospitalization rates, by age group, race, and sex, per 1,000 children, Tennessee, USA, 1998–2013. A) <2 years of age; B) 2–4 years of age; C) 5–17 years of age. Asterisks indicate groups with a significantly higher rate than white girls within each period, determined on the basis of the 95% CI of the respective rate ratio (not shown). Error bars indicate 95% CIs of hospitalization rate. Periods were defined as follows: pre-PCV7, 1998–1999; early PCV7, 2001–2005; late PCV7, 2006–2009; and post-PCV13, 2011–2013.